Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenetic Biosciences, Inc. - Common Stock (NQ:XBIO)

1.798 -0.073 (-3.88%)
Delayed Quote Updated: 1:47 PM EST, Nov 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenetic Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance
Research examines a self-reinforcing resistance niche created by extracellular chromatin released during CAR T-cell killing and its reversal by DNase I Presentation selected for ASH scientific session... 
From Xenetic Biosciences, Inc.
Via ACCESS Newswire
News headline image
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
First clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical Center Initial... 
From Xenetic Biosciences, Inc.
Via ACCESS Newswire
News headline image
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune... 
From Xenetic Biosciences, Inc.
Via ACCESS Newswire
News headline image
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
From Xenetic Biosciences, Inc.
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
Via ACCESS Newswire
News headline image
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
Via ACCESS Newswire
News headline image
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
Via ACCESS Newswire
News headline image
Why Did UPB Stock Pop 20% In Pre-Market Today? ↗
The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma. 
Via Stocktwits
News headline image
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges ↗
Benzinga Edge Stock Rankings evaluate companies across four key factors. Here are three big companies that stood out this week. 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Friday? ↗
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
Via ACCESS Newswire
News headline image
4 Stocks In The Same Sector Just Made A Huge Leap In Momentum Rankings ↗
Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names have been picking up steam as the market rally broadens and major indexes continue to reach new highs.... 
Via Benzinga
News headline image
Which stocks are moving before the opening bell on Thursday? ↗
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN – Innovators Driving Next Tech, Blockchain, AI Wave – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Gains 150 Points; US Mortgage Applications Decline ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.